RxDoctor Payments Data

Roger Matthews, DO

Family Medicine · Golden, CONPI 1104820570

Payments from drug & device makers

$1,404in general payments, 2019–2025

Across 80 payments — averaging $17.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$256
  • Johnson & Johnson$213
  • AstraZeneca$149
  • Grifols USA, LLC$92
  • Pfizer$67
  • Hologic Sales And Service, LLC$56
  • plus $570 from 22 others

What the payments were for

  • Food & beverage$1,39399%
  • Education$111%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,404 in reported general payments places this provider in the 80th percentile of 2,079 family medicine providers in Colorado.

See all family medicine providers in Colorado

Medicare billing

Part B allowed, 2024
$65,750
Medicare patients
232
Services billed
874

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide17$28,460
EliquisApixaban28$27,792
MounjaroTirzepatide20$21,540
XareltoRivaroxaban12$19,247
TrulicityDulaglutide12$18,856
Valsartan64$2,016
Atorvastatin Calcium170$1,543
Ezetimibe86$1,513
Rosuvastatin Calcium152$1,245
Boostrix TdapDiphth,pertuss(Acell),tet Vac14$976
Gabapentin76$963
Losartan Potassium82$872
Omeprazole56$809
Amlodipine Besylate64$808
Levothyroxine Sodium88$791

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$15$40,39632 claims
Novo NordiskOzempic$38$28,46017 claims
PfizerEliquis$67$27,79228 claims
Johnson & JohnsonXarelto$213$19,24712 claims
AbbVieSynthroid$256$71518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,079 family medicine providers in Colorado.

Other family medicine in Golden

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →